The efficacy and safety of rivaroxaban monotherapy are consistent across all age groups of patients with atrial fibrillation and stable coronary artery disease, a study confirms.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/rivaroxaban-alone-comparable-combination-therapy-across-age-2025a1000lxm?src=rss
Author :
Publish date : 2025-08-20 02:59:00
Copyright for syndicated content belongs to the linked Source.
